{"id":642638,"date":"2023-03-14T20:06:01","date_gmt":"2023-03-14T20:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=642638"},"modified":"2023-03-14T20:06:01","modified_gmt":"2023-03-14T20:06:01","slug":"graftversushost-disease-gvhd-emerging-and-marketed-drugs-assessment-2023-updates-clinical-trials-latest-fda-ema-and-pmda-approvals-treatment-outlook-competitive-landscape-key-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/graftversushost-disease-gvhd-emerging-and-marketed-drugs-assessment-2023-updates-clinical-trials-latest-fda-ema-and-pmda-approvals-treatment-outlook-competitive-landscape-key-companies_642638.html","title":{"rendered":"Graft-Versus-Host Disease (GVHD) Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, Key Companies"},"content":{"rendered":"
\n
\"Graft-Versus-Host<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight\u2019s assessment, globally, about 60+ key pharma and biotech companies are working on 60+ pipeline drugs in the Graft-Versus-Host Disease (GVHD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n

Graft versus Host Disease (GvHD) market is expected to grow significantly owing to the market penetration of approved therapies and the anticipated label expansion and readily adoption of emerging therapies. Moreover, the growing awareness of cellular therapies, regulatory assistance for research, and innovation are also expected to contribute to the market’s growth.<\/em><\/p>\n

Major pharma giants such as CSL Behring [CSL 964 Alpha-1 antitrypsin (AAT)], Medac [obnitix (MC0518)], Equillium\/Biocon [itolizumab], OncoImmune\/Merck (MSD) [MK-7110 (CD24Fc)], ElsaLys Biotech\/Mediolanum Farmaceutici Spa [Leukotac (inolimomab)], Xenikos [T-Guard], Mesoblast\/Osiris Therapeutics [RYONCIL (remestemcel-L; prochymal)], Syndax Pharmaceutical [axatilimab (SNDX-6532)], Regimmune Corporation (RGI-2001)<\/strong> and several others are actively involved in the development of novel therapies.<\/em><\/p>\n

“Graft-Versus-Host Disease  (GVHD) Pipeline Insight, 2023<\/strong>” report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Graft-Versus-Host Disease Market. <\/p>\n

The Graft-Versus-Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n

\"Graft-Versus-Host<\/p>\n

Graft-Versus-Host Disease (GVHD) Pipeline Analysis<\/strong><\/a><\/p>\n

The report provides insights into: <\/strong><\/p>\n